Article    Table of Contents                    Full Text of this article Free    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Salpeter, S. R.    Salpeter, E. E.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Cardioselective ß-Blockers in Patients with Reactive Airway Disease

A Meta-Analysis

Shelley R. Salpeter, MD; Thomas M. Ormiston, MD; and Edwin E. Salpeter, PhD

5 November 2002 | Volume 137 Issue 9 | Pages 715-725

Objective: To assess the effect of cardioselective ß-blockers on respiratory function of patients with reactive airway disease.

Data Sources: Comprehensive searches of the EMBASE, MEDLINE, and CINAHL databases from 1966 to May 2001 and scanning of references of the identified articles and related reviews.

Study Selection: Randomized, blinded, placebo-controlled trials that studied the effects of cardioselective ß-blockers on FEV₁, symptoms, and the use of inhaled ß₂-agonists in patients with reactive airway disease were selected. Interventions studied were the administration of a cardioselective ß-blocker and administration of ß₂-agonist after the study drug.

Data Extraction: Outcomes measured were the change in FEV₁ from baseline, the number of patients with respiratory symptoms, and the use of inhaled ß₂-agonists with active treatment compared with placebo.

Data Synthesis: Nineteen studies on single-dose treatment and 10 studies on continued treatment were included. Administration of a single dose of a cardioselective ß-blocker was associated with a 7.46% (95% CI, 5.59% to 9.32%) decrease in FEV₁ and a 4.63% (CI, 2.47% to 6.78%) increase in FEV₁ response to ß-agonist compared with placebo, with no increase in symptoms. Trials lasting from 3 days to 4 weeks produced no significant change in FEV₁ (–0.42% [CI, –3.74% to 2.91%]), symptoms, or inhaler use compared with placebo but maintained an 8.74% (CI, 1.96% to 15.52%) increase in ß-agonist response. No significant treatment effect in terms of FEV₁ was found in patients with concomitant chronic obstructive pulmonary disease, whether single doses (change in FEV₁, –5.28% [CI, –10.03% to –0.54%]) or continued treatment (change in FEV₁, 1.07% [CI, –3.3% to 5.44%]) was given.

Conclusions: Cardioselective ß-blockers do not produce clinically significant adverse respiratory effects in patients with mild to moderate reactive airway disease. The results were similar for patients with concomitant chronic airways obstruction. Given their demonstrated benefit in such conditions as heart failure, cardiac arrhythmias, and hypertension, cardioselective ß-blockers should not be withheld from patients with mild to moderate reactive airway disease.

Editors' Notes Context Although ß-blockers improve clinical outcomes in many patients with cardiovascular disease, clinicians sometimes avoid these agents in patients with concomitant lung disease because they fear precipitation of acute bronchospasm. Contribution This meta-analysis of 29 randomized trials shows that cardioselective-blockers (ß1-blockers), given for a few days to a few weeks, do not significantly worsen pulmonary function or respiratory symptoms and do not lead to increased use of inhalers in patients with mild to moderate reactive (reversible) airway disease. Cautions The studies in this meta-analysis were short, evaluated only cardioselective ß-blockers, and did not include patients with severe or irreversible airway disease. –The Editors

 

Author and Article Information

From Stanford University School of Medicine, Palo Alto, California; Santa Clara Valley Medical Center, San Jose, California; and Cornell University, Ithaca, New York.

Acknowledgments: The authors thank Steve Milan for guidance with the Cochrane review, Toby Lasserson for technical assistance, and Karen Blackhall for coordinating the trials search.

Requests for Single Reprints: Shelley Salpeter, MD, Department of Medicine, Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128; e-mail, shelley.salpeter{at}hhs.co.santa-clara.ca.us.

Current Author Addresses: Dr. S. Salpeter: Department of Medicine, Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128.

Dr. Ormiston: Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128.

Dr. E. Salpeter: Center for Radiophysics and Space Research, Cornell University, 612 Space Sciences Building, Ithaca, NY 14853.

Author Contributions: Conception and design: S.R. Salpeter, T.M. Ormiston.

Analysis and interpretation of the data: S.R. Salpeter, T.M. Ormiston, E.E. Salpeter.

Drafting of the article: S.R. Salpeter, T.M. Ormiston.

Critical revision of the article for important intellectual content: S.R. Salpeter, T.M. Ormiston.

Final approval of the article: S.R. Salpeter, T.M. Ormiston, E.E. Sal-peter.

Provision of study materials or patients: S.R. Salpeter, T.M. Ormiston.

Statistical expertise: E.E. Salpeter.

Collection and assembly of data: S.R. Salpeter, T.M. Ormiston.

Related articles in Annals:

Editorials
Fresh Air and ß-Blockade
Paul E. Epstein

Annals 2002 137: 766-767. [Full Text]  

Summaries for Patients
Are Beta-1–Blockers Safe for Patients with Lung Disease?

Annals 2002 137: I-31. [Full Text]  

Letters
Use of ß-Blockers in Patients with Reactive Airway Disease
David J. Shulan, Michael Katlan, AND Mollie Lavsky-Shulan

Annals 2003 139: 304. [Full Text]  

Letters
Use of ß-Blockers in Patients with Reactive Airway Disease
Shelley R. Salpeter AND Thomas M. Ormiston

Annals 2003 139: 304. [Full Text]  

This article has been cited by other articles:

				J. A. Falk, S. Kadiev, G. J. Criner, S. M. Scharf, O. A. Minai, and P. Diaz Cardiac Disease in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 543 - 548. [Abstract] [Full Text] [PDF]

				Y. Ling, W. Saleem, and C. D. Shee Concomitant use of {beta}-blockers and {beta}2-agonists Eur. Respir. J., April 1, 2008; 31(4): 905 - 906. [Full Text] [PDF]

				D. H Au Use of {beta} blockers in patients with COPD Thorax, April 1, 2008; 63(4): 296 - 298. [Full Text] [PDF]

				D. M Shavelle Long term medical treatment of stable coronary disease Heart, November 1, 2007; 93(11): 1473 - 1477. [Full Text] [PDF]

				C. C Lang and D. M Mancini Non-cardiac comorbidities in chronic heart failure Heart, June 1, 2007; 93(6): 665 - 671. [Abstract] [Full Text] [PDF]

				H. K. Pannu, W. Alvarez Jr., and E. K. Fishman {beta}-Blockers for Cardiac CT: A Primer for the Radiologist Am. J. Roentgenol., June 1, 2006; 186(6_Supplement_2): S341 - S345. [Abstract] [Full Text] [PDF]

				A. Auerbach and L. Goldman Assessing and Reducing the Cardiac Risk of Noncardiac Surgery Circulation, March 14, 2006; 113(10): 1361 - 1376. [Full Text] [PDF]

				S. Andreas, S. D. Anker, P. D. Scanlon, and V. K. Somers Neurohumoral Activation as a Link to Systemic Manifestations of Chronic Lung Disease Chest, November 1, 2005; 128(5): 3618 - 3624. [Abstract] [Full Text] [PDF]

				D. Redelmeier, D. Scales, and A. Kopp {beta} blockers for elective surgery in elderly patients: population based, retrospective cohort study BMJ, October 22, 2005; 331(7522): 932. [Abstract] [Full Text] [PDF]

				M. Egred, S. Shaw, B. Mohammad, P. Waitt, and E. Rodrigues Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease QJM, July 1, 2005; 98(7): 493 - 497. [Abstract] [Full Text] [PDF]

				H. J. van der Woude, J. Zaagsma, D. S. Postma, T. H. Winter, M. van Hulst, and R. Aalbers Detrimental Effects of {beta}-Blockers in COPD: A Concern for Nonselective {beta}-Blockers Chest, March 1, 2005; 127(3): 818 - 824. [Abstract] [Full Text] [PDF]

				C. I Lindblad, M. B Artz, C. F Pieper, R. J Sloane, E. R Hajjar, C. M Ruby, K. E Schmader, and J. T Hanlon Potential Drug-Disease Interactions in Frail, Hospitalized Elderly Veterans Ann. Pharmacother., March 1, 2005; 39(3): 412 - 417. [Abstract] [Full Text] [PDF]

				M. Zaugg, C. Schulz, J. Wacker, and M. C. Schaub Sympatho-modulatory therapies in perioperative medicine Br. J. Anaesth., July 1, 2004; 93(1): 53 - 62. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis Chest, June 1, 2004; 125(6): 2309 - 2321. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma Ann Intern Med, May 18, 2004; 140(10): 802 - 813. [Abstract] [Full Text] [PDF]

				Z. Callaerts-Vegh, K. L. J. Evans, N. Dudekula, D. Cuba, B. J. Knoll, P. F. K. Callaerts, H. Giles, F. R. Shardonofsky, and R. A. Bond Effects of acute and chronic administration of {beta}-adrenoceptor ligands on airway function in a murine model of asthma PNAS, April 6, 2004; 101(14): 4948 - 4953. [Abstract] [Full Text] [PDF]

				A. D. Auerbach and J. Kleinbart Update in Hospital Medicine Ann Intern Med, March 2, 2004; 140(5): 363 - 369. [Full Text] [PDF]

				J F Kirwan, J A Nightingale, C Bunce, and R Wormald Do selective topical {beta} antagonists for glaucoma have respiratory side effects? Br. J. Ophthalmol., February 1, 2004; 88(2): 196 - 198. [Abstract] [Full Text] [PDF]

				M. R Andrus, K. P Holloway, and D. B Clark Use of {beta}-Blockers in Patients with COPD Ann. Pharmacother., January 1, 2004; 38(1): 142 - 145. [Abstract] [Full Text] [PDF]

				G. Porat, K. Berend, and P. August Initial Treatment of Hypertension N. Engl. J. Med., September 11, 2003; 349(11): 1090 - 1091. [Full Text] [PDF]

				D. J. Brotman and S. D. Frost The JNC 7 Hypertension Guidelines JAMA, September 10, 2003; 290(10): 1313 - 1314. [Full Text] [PDF]

				D. J. Shulan, M. Katlan, and M. Lavsky-Shulan Use of {beta}-Blockers in Patients with Reactive Airway Disease Ann Intern Med, August 19, 2003; 139(4): 304 - 304. [Full Text] [PDF]

				J B. Jura and A. R Blanchard Review: cardioselective {beta}1 blockers given for 3 days to 4 weeks do not reduce respiratory function in reactive airway disease Evid. Based Med., May 1, 2003; 8(3): 73 - 73. [Full Text] [PDF]

				I. Malik JournalScan Heart, February 1, 2003; 89(2): 239 - 240. [Full Text] [PDF]

				E Gamble Cardioselective {beta} blockers do not cause adverse respiratory effects in mild to moderate reactive airway disease Thorax, February 1, 2003; 58(2): 142 - 142. [Full Text]

				Cardioselective {beta}-Blockers in Patients with Reactive Airways Journal Watch (General), November 26, 2002; 2002(1126): 3 - 3. [Full Text]

				P. E. Epstein Fresh Air and {beta}-Blockade Ann Intern Med, November 5, 2002; 137(9): 766 - 767. [Full Text] [PDF]